Racura Oncology Ltd

RAC.AX·ASX·Healthcare

Compare

1.5850+0.0250 (+1.60%)today

At close: Oct 23, 4:10 PM AEDT · May be delayed up to 20 min · AUD

Key statistics

Previous close1.5600

Open1.5900

Day range1.52001.5900

52-week range1.52003.7900

Off day high−0.31%

Off 52-week high−58.18%

Volume60.65K

Avg. volume (3M)78.89K

Market cap310.77M

EPS (TTM)-0.0600

Forward P/E-15.39

P/E ratio (TTM)—

Dividend yield—

Beta (5Y)0.91

Shares outstanding196.07M

Short interest—

Earnings dateJul 20, 2025 (est.)

Analyst target—

Profit margin0.00%

Related companies

Compare ›

Also based in Sydney, Australia, then elsewhere in Australia.

Company	Mkt cap	Price	Today
Commonwealth Bank of AustraliaCWW.F · Sydney, NSW	168.89B	101.02	+3.72%
Westpac Banking CorporationWBC.F · Sydney, NSW	77.47B	22.69	+3.44%
Atlassian CorporationTEAM · Sydney, NSW Odds	57.62B	227.61	+1.99%
QBE Insurance Group LimitedQBE.AX · Sydney, NSW	39.20B	26.24	−1.00%
Brambles LimitedBXB.AX · Sydney, NSW	28.64B	21.57	−0.37%
Evolution Mining LimitedWE7.F · Sydney, NSW	14.73B	7.20	−0.77%
Insurance Australia Group LimitedIAG.AX · Sydney, NSW	20.67B	8.84	−0.95%
Scentre GroupSCG.AX · Sydney, NSW	18.51B	3.5400	+0.28%

What visitors to RAC.AX's page also look at.

Company	Mkt cap	Price	Today
IMUGENE FPO [IMU]IMU.AX	19.39M	0.0350	−7.89%
PARA BIO FPO [PAR]PAR.AX	153.48M	0.2450	0.00%
RECCE LTD FPO [RCE]RCE.AX	100.90M	0.3300	−1.49%
IMMUTEP FPO [IMM]IMM.AX	32.42M	0.0220	−4.35%
PRESCIENT FPO [PTX]PTX.AX	59.48M	0.0520	−3.70%

From the 4Conservative instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 20 min.

Latest news

All RAC.AX news ›

@PRNewswire·6d agoPositive

Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer

Oct 12, 2026, 07:00 ET The HARNESS-1 Safety Review Committee identified no dose-limiting toxicities or treatment-related safety concerns in either Cohort 1 patient during the safety observation period and has recommended the trial proceed…

From articles in the 4Search news index.

About

Profile ›

Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in Dece…

SectorHealthcare

IndustryBiotechnology

Chief executiveDaniel Tillett

HeadquartersSydney, NSW, Australia

Websiteracuraoncology.com

Earnings

Reported EPS
Estimate

Next report: Sun, Jul 20, 2025 (estimated)

Quarterly results

Financials ›

Revenue
Net income

Prices may be delayed up to 15 min. Not investment advice.

Track record

Leaderboard ›

Days on the list	30 d	1 yr	Best
Trending	0	0	—

Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).

Not eligible for Small-cap gainers, Aggressive small caps (U.S. stocks worth under $2 billion only).

Not eligible for Growth tech (U.S. technology stocks only).

Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).

A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use. How to use Finance